Abstract: The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Abstract: The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Abstract: The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Abstract: The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates useful for making the pyrimidone compounds. Additionally, pharmaceutical compositions and methods for treating those infected with HIV are encompassed.

Abstract: The present invention relates to methods of diagnosis, therapy, and screening of new therapeutic compounds in the field of osteogenesis, based on the differential expression observed for the genes of the invention, represented by SEQ ID No 2, 7, 22, 25, 33, 35, 37, 38, 42, 47, 64, 69 or 77, 82, 97, 100, 108, 110, 112, 113, 117, 122, 139, 151, 158, 160, 172, 182, 184, 187, 188, 194.

Abstract: The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

Abstract: The present invention relates to methods of diagnosis, therapy, and screening of new therapeutic compounds in the field of osteogenesis, based on the differential expression observed for the genes of the invention, represented by SEQ ID No 1 to SEQ ID No 150, or SEQ ID No 151, 152 or 153, or SEQ ID No 154 to SEQ ID No 196, or SEQ ID No 197 to SEQ ID No 210, or SEQ ID No 211 to SEQ ID No 229, or SEQ ID No 230 to SEQ ID No 234, or SEQ ID No 235 to SEQ ID No 245.

Abstract: The present invention relates to a highly efficient, high-throughput method for the identification and elimination of redundancy in a population of nucleic acid molecules using microarrays. This method involves a reiterative subtraction protocol that creates a library that becomes more biased toward unknown genes with each successive round. The removal of repetitive and previously characterized nucleic acids from the library allows the identification of low-abundance mRNA from sources of interest and enhances the rate of novel gene discovery. The present invention is also useful for the removal of contaminating nucleic acids from cloning libraries.

Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptides of the present invention are human slit polypeptides. The invention also relates to identifying mesenchymal stem cells (MSCs) or other cells comprising such polypeptides or polynucleotides that encode the polypeptides.

Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptides of the present invention are human Hox C10 polypeptides. The invention also relates to identifying mesenchymal stem cells (MSCs) or other cells comprising such polypeptides or polynucleotides that encode the polypeptides.

Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptides of the present invention are human Hox C10 polypeptides. The invention also relates to identifying mesenchymal stem cells (MSCs) or other cells comprising such polypeptides or polynucleotides that encode the polypeptides.

Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptides of the present invention are human slit polypeptides. The invention also relates to identifying mesenchymal stem cells (MSCs) or other cells comprising such polypeptides or polynucleotides that encode the polypeptides.

Abstract: A nonwoven composite web suitable for use as a battery separator is formed by a wet process on a papermaking machine. The nonwoven composite material is made from a furnish of nylon binder fibers and nylon staple fibers. The web coming off the papermaking machine is dried using infra-red dryers followed by heated dryer cans. After drying, the web is thermally bonded using heated calendar rolls. The nylon binder fibers melt as the web passes through the calendar rolls and thermally bond the nylon staple fibers of the web when the melted binder fiber material fuses upon cooling. The use of dryer cans to dry and partially bond the web eliminates the need for surfactant treatment to improve potassium hydroxide absorption.

Abstract: An apparatus and related process for entangling a staple fibrous web which employs divergent fluid jets. The web is advanced through an entangling station on a conveying means which supports an entangling member having a symmetrical pattern of fluid pervious void areas. The divergent jet sprays which are disposed above the entangling member direct a continuous curtain of fluid onto the web, coacting with the entangling member to entangle web fibers into a coherent lattice structure. The divergent jet sprays are provided by nozzles having wide orifice diameters which accommodate less complex fluid recirculation and filtration systems than employed in prior art columnar jet processes.